Background. It is unclear whether pandemic 2009 influenza A (pH1N1) infection caused more significant disease among hospitalized adults than seasonal influenza.
related to confirmed infections had been reported to the World Health Organization [3] . Studies have shown that although most ambulatory patients with pH1N1 influenza develop mild upper respiratory-tract symptoms similar to those seen with seasonal influenza [4] [5] [6] [7] , some may develop lower respiratory complications and pneumonia, leading to hospitalizations [7, 8, 9, 10] . About 9%-31% of hospitalized patients had required intensive care, and 14%-46% of them died [1, 2, [9] [10] [11] [12] [13] [14] [15] [16] [17] . However, few studies have examined whether, among hospitalized adults, the morbidity and mortality associated with pH1N1 influenza exceed those associated with seasonal influenza, which may also cause severe disease [18] [19] [20] [21] [22] [23] [24] . In this study, we report the complications, treatment and outcomes in a large cohort of adults hospitalized with pH1N1 influenza and compare them with findings in a recent seasonal influenza cohort. Such information may improve our understanding on the course and impact of this novel disease in its more severe form and lead to better patient management.
METHODS

Study Population
A prospective, observational cohort study was conducted in all adults (aged .16 years) hospitalized for polymerase chain reaction (PCR)-confirmed, pH1N1 infection in 2 hospitals in Hong Kong during a 12-month period (from 1 June 2009 to 31 May 2010, the entire first wave in Hong Kong) [23] . We compared the findings with those in the whole seasonal influenza cohort (confirmed by culture and/or antigen assay) studied prospectively in the same hospitals from 1 January 2007 to 31 December 2008 [19] . The 2 participating hospitals are acute-care general public hospitals operating under the Hospital Authority of Hong Kong and serve an urban population of .1.5 million [19] . Ethical approval for study was obtained from the institutional review boards of the Chinese University of Hong Kong and the Hospital Authority of Hong Kong.
Case Finding and Management of Influenza
Hospital admission procedures for adults with influenza have been described elsewhere [19, 23] . In brief, patients presenting with acute febrile respiratory illnesses would be considered for hospitalization if they had developed potentially serious medical conditions or complications, exacerbation of underlying illnesses, or severe systemic and respiratory symptoms that were unmanageable at home [19, 23] . They were directly admitted to designated medical infectious diseases wards and put on a strict droplet precaution. Regardless of the perceived etiology, nasopharyngeal aspirate (NPA) samples were collected from these patients at presentation to test for the pH1N1 virus, using a specific real-time reverse-transcription (RT) PCR assay [23] . NPA sample collection was omitted only in a minority of patients whose diagnosis had been confirmed by RT-PCR analysis of nasal or throat swab samples before admission.
Antiviral treatment for pH1N1 infection had not been standardized, and it evolved during the study period [1, 23, 25, 26] . According to local recommendations [25] , neuraminidase inhibitor (NAI) treatment would be considered for all pH1N1-infected patients who require hospitalization, but no restrictions were made on the choice (oseltamivir or zanamivir) or the regimen used. Resistance to NAI was reported to be rare [1, 23, 25] . Standard dosing regimens (eg, oral oseltamivir, 75 mg twice daily, or inhalational zanamivir, 10 mg twice daily for 5 days), were most commonly applied [1, 23, 25, 26] ; however, clinicians were allowed to increase the dose (eg, 150 mg twice daily) and/or extend the duration to .5 days if deemed necessary. Because this study involved no controlled intervention, patients' medical complications were managed according to usual clinical procedures [19, 23] . Sputum (or tracheal aspirate in intubated patients) was routinely collected for bacterial culture, and blood was also obtained for culture from patients with signs of sepsis; antibacterial treatment was given according to existing guidelines [27] .
Clinical Data Collection and Definitions
During the study period, all patients with PCR-confirmed pH1N1 influenza were identified and enrolled by the laboratory and clinical research teams daily [19, 23, 28] . Clinical information was then recorded systemically by designated research staff, using a standardized research tool (identical for the seasonal influenza cohort) [19, 23] . Medical complications related to influenza infection (which often were the reasons for hospitalization) were defined as new or exacerbated medical problems as documented by appropriate clinical, laboratory, and radiographic studies [19] . Radiographic pneumonia, acute bronchitis, and exacerbation of underlying airway diseases were classified as ''pulmonary'' (respiratory) complications. Concomitant, acutely onset cardiovascular, gastrointestinal, neurologic and renal conditions were classified as ''extrapulmonary'' complications (Table 1) . Patients with R1 pulmonary or extrapulmonary complication were regarded as having complicated influenza illnesses. Bacterial superinfection was defined by isolation of a significant pathogen in R1 respiratory or blood sample from symptomatic patients. Antiviral treatment was defined as the use of an NAI (oseltamivir or zanamivir) for .1 day, and the interval between symptom onset and treatment initiation was calculated for each patient. The outcome ''death'' was defined as death of any cause that occurred during hospitalization. All patients were followed up for R30 days. ''Adverse outcomes'' were defined as the requirement of intensive care unit (ICU) admission for ventilatory and organ support [23] and/or death that occurred during hospitalization, either in the ICUs or in the medical wards (ie, ''ICU admission and/or death,'' in contrast to patients who survived and did not require ICU admission) [11, 16, 19] . This composite outcome measure represented the development of critical illnesses for both pandemic H1N1 and seasonal influenza, because such patients could be treated in either setting during the study periods.
Virologic Investigations
All NPA samples collected at presentation were subjected to viral antigen detection for influenza A and B, respiratory syncytial virus, and parainfluenza viruses by an immunofluorescence assay (or an immunochromatographic assay) as described elsewhere (LIGHT DIAGNOSTICS, Chemicon, MA; BinaxNOWR, Cranfield) [19, 28] . During the study period, a real-time RT-PCR assay specific for the hemagglutinin gene of the pH1N1 virus was additionally performed in all NPA samples, using methods described elsewhere [23, 29] . These assays were performed under biosafety level II containment, and the results were generally available to clinicians within several hours to assist in case management. Subsequent isolation of pH1N1 virus was performed by the National Influenza Centre at the Centre for Health Protection in Hong Kong [23] .
Statistical Analysis
Findings in patients with pandemic H1N1 influenza were recorded and compared with those in patients with seasonal influenza. Descriptive statistics were reported as means 6 standard deviations or medians with interquartile ranges, based on data distribution. Student's t tests and v2 were used for univariate comparisons, whenever appropriate. Variables with P values of %.1 in univariate analyses were entered into backward stepwise logistic regression models to determine independent factors associated with adverse outcomes. Adjusted odds ratios (ORs) and 95% confidence interval (CIs) were calculated and reported for each explanatory variable [28] . KaplanMeier analysis and the log-rank test were used to study survival within 30 days in patients with pandemic influenza, in relation to antiviral use (treatment within 96 h after onset vs no treatment or treatment started .96 h after onset). This time interval was chosen for comparison based on findings of our previous study in patients with seasonal influenza, which showed improved survival when treatment was started within 96 h [19] . In all analyses, P values of , .05 were considered to indicate statistical Length of stay among survivors, mean 6 SD, days 7.7 6 10.5
NOTE. Data represent percentages of patients, unless other units are specified. ICA, immunochromatographic assay; IFA, immunofluorescence assay; RT-PCR, reverse-transcription polymerase chain reaction; SD, standard deviation.
a Comorbid condition, any: included both comorbid condition, major, and chronic lung disease. Patients may have R1 comorbid illness [19, 23, 28] . Major comorbid condition included congestive heart failure; cerebrovascular, neoplastic, and chronic liver or renal disease; other chronic cardiovascular and neurologic conditions (except hypertension); diabetes mellitus; autoimmune disorders; and immunosuppressant therapy. Chronic lung diseases included chronic obstructive pulmonary disease, asthma, bronchiectasis, and pulmonary fibrosis.
b Obesity was defined as a body mass index of .30. Six of these patients had obstructive sleep apnea.
c The percentages for pregnancy represent percentages of reproductiveage female patients.
d Positive results of IFA or ICA in nasopharyngeal aspirate (NPA) samples. All pandemic H1N1 influenza was confirmed by RT-PCR (NPA samples, 76.2%; nasal or throat swab samples, 23.8%) [23, 33] .
e Respiratory complications (at presentation) included pneumonia (radiographic pneumonia, as diagnosed by managing physicians) and airway disease (acute exacerbations of asthma or chronic obstructive pulmonary disease; acute bronchitis).
f Extrapulmonary complications included the following categories: cardiovascular (acute coronary syndrome, decompensated heart failure, arrhythmia, myocarditis [pandemic H1N1, n 5 3; seasonal, n 5 0]), neurologic (encephalopathy, confusion or delirium, seizure, stroke, transient ischemic attack), gastrointestinal (severe vomiting, diarrhea, abdominal pain, gastrointestinal bleeding), renal (serum creatinine levels increased .2-fold from baseline and/or requirement of dialysis). Some patients had R1 pulmonary or extrapulmonary complication [19, 23, 28] . Patients with ''uncomplicated'' influenza were hospitalized for management of severe systemic or respiratory symptoms (eg, high fever, chills or rigor, myalgia, sore throat, severe cough, shortness of breath, headache, dizziness, dehydration), in the absence of respiratory or extrapulmonary complications [19, 23, 28] .
g The diagnosis of bacterial superinfection was based on positive cultures of respiratory tract (sputum, endotracheal aspirate) specimens and/or blood cultures; infections with onset .2 days after admission were defined as hospital-acquired infections [19] .
h For antiviral treatment, oseltamivir (n 5 352) and zanamivir (n 5 31) were used for 2009 H1N1 infection; 15 patients received both agents. In 74 patients (21%), the oseltamivir dosage was .75 mg twice daily (eg, 150 mg twice daily); 1 patient received oseltamivir and then peramivir. For patients with seasonal influenza, only oseltamivir (dosage, 75 mg twice daily) was used [19] . significance. All probabilities were 2 tailed. Statistical analysis was performed using PASW Statistics software (version 17.0).
RESULTS
Characteristics and Outcomes in Study Cohort
Altogether, 382 patients with PCR-confirmed pH1N1 infection were studied (Table 1) . Their mean age (6 standard deviation) was 46.5 6 19.6 years; 182 (47.6%) had comorbid conditions, and 31 (8.1%) were pregnant women. The mean interval from onset to presentation was 2.5 6 2.6 days. The positive rate of antigen assays (immunofluorescence or immunochromatographic assay) was only 53.5%, compared with real-time RT-PCR. Nearly all patients (96.3%) received antiviral treatment during their course of illness. Oseltamivir was the most commonly prescribed antiviral agent (in 352 of 368 patients), followed by zanamivir (in 31 of 368). In .40% of cases, treatment was initiated .48 h after onset (%48 h, 52.4%; %96 h, 76.7%; %144 h, 85.6%; %192 h, 93.2%). At least one complication was noted at presentation in 67.8% of patients; bacterial superinfection was evident in 11.3%. Twenty-seven patients (7.1%) required ICU admission for support, and 12 (3.1%) died during hospitalization. The causes of death were fulminant pneumonia in 10 patients and chronic obstructive pulmonary disease or respiratory failure in 2 (extrapulmonary complications occurred in 7 of 12); the median interval before death was 7 days (interquartile range, 1-16 days). Overall, 35 patients (9.2%) suffered the adverse outcomes of ICU admission and/or death; among these patients, cumulatively, 14 (40.0%), 16 (45.7%), 24 (68.6%), and 27 (77.1%) had received antiviral treatment %48, %96, %144, and %192 h after onset, respectively. After adjustment for confounders, including age and comorbid conditions, it was shown that lack of treatment within 96 h was significantly associated with higher risk of deterioration (adjusted OR, 5.55; 95% CI, 2.61-11.80; P , .001]. The risk of adverse outcomes was found to increase with the interval between symptom onset and treatment initiation within the first week of illness (adjusted OR, 1.17 per day after onset; 95% CI, 1.04-1.31; P 5 .007).
Kaplan-Meier analyses showed that in patients hospitalized for pH1N1 influenza, antiviral treatment started within 48 h from onset was associated with better survival (log-rank test, P 5 .015) within 30 days. Notably, treatment started within 96 h was also associated with better survival within 30 days, compared with no or later treatment (log-rank test, P , .001)( Figure  1) . Cox proportional hazards model analyses that adjusted for confounders revealed similar results (adjusted hazards ratio, .05; 95% CI, .01-.40; P 5 .005). Results of the Cox models and subgroup analyses are provided in Supplementary Material 1.
Comparisons Between Pandemic H1N1 and Seasonal Influenza
The seasonal influenza cohort has been described (n 5 754) (January-December 2007, n 5 442; January-December 2008, n 5 312; influenza A, 72%; influenza B, 28%) [19] . Patients with pH1N1 infection were significantly younger than those with seasonal influenza (46.5 6 19.6 vs 69.7 6 18.6 years, P , .001), and fewer had comorbid conditions (47.6% vs 63.8%, P , .001) (Supplementary Material 2) . The interval from onset to presentation was significantly longer (P , .001), and the rate of positive antigen assays in NPA samples was about 30% lower (P , .001). Antiviral use was more frequent (96.3% vs 52.4%; P , .001). Although overall slightly fewer patients in the pH1N1 cohort had complications (67.8% vs 77.1%), a higher proportion had required invasive or noninvasive ventilatory support (8.4% vs 5.2%; P 5 .039) or ICU care (7.1% vs 1.9%; P , .001). The overall rate of adverse outcomes (ICU admission and/or death) also tended to be higher (9.2% vs 6.5%; P 5 .105). However, when results were stratified according to age, rates of these adverse outcomes were found to be higher among the younger patients with pH1N1 influenza, compared with patients with seasonal influenza ( When patients with complicated influenza illnesses were compared (Table 2) , we found that though pneumonia and acute airway diseases were the most common complications in both groups (respiratory, 77.2% vs 79.9%), extrapulmonary (neurologic, gastrointestinal, or renal) complications were significantly more common with pH1N1 influenza (34.0% vs 20.8%; P , .001). Lymphopenia and elevated transaminase levels were also more frequently noted in patients with pH1N1 influenza (both P , .05). A higher proportion of patients with pH1N1 influenza had required ventilatory support and ICUlevel care (both P , .05), and the rate of adverse outcomes (ICU admission and/or death) was also significantly higher than in patients with seasonal influenza (13.5% vs 8.4%; P 5 .022).
After adjustment for age, comorbid conditions, delayed presentation, antiviral use and other confounders, we found that pH1N1 influenza was associated with a higher risk of adverse outcomes (ICU admission and/or death), compared with seasonal influenza (adjusted OR, 2.13; 95% CI, 1.25-3.62; P 5 .005). Bacterial superinfection and the presence of pulmonary or extrapulmonary complications were also found to be associated with adverse outcomes in the final logistic regression model (Table 3) .
Factors Affecting Survival in pH1N1 and Seasonal Influenza
Among hospitalized patients with pH1N1 influenza who did not receive antiviral treatment within 96 h after onset (n 5 89), the mortality rate was 9.0%, which was higher than that observed among patients with seasonal influenza (5.8%) who did not receive such treatment (n 5 371). After controlling for confounders, we found that if antiviral treatment was not received within 96 h, pH1N1 influenza was independently associated with a higher risk of death (OR, 6.85; 95% CI, 1.64-28.65; P 5 .008]( Table 4) . On the other hand, if antiviral treatment was received within 96 h, the mortality rates were 1.4% and 4.5% for pH1N1 and seasonal influenza, respectively. Multivariate analysis performed for this treated group did not show a significant difference in mortality between the 2 influenza cohorts (data not shown).
Finally, a combined analysis of all cases (n 5 1136) showed that older age, male sex, the presence of comorbid conditions, and bacterial superinfection were factors independently associated with increased risk of death, whereas antiviral treatment within 96 h after onset was associated with reduced risk of death among adults hospitalized for pH1N1 or seasonal influenza (Supplementary Material 3) .
DISCUSSION
Our results are consistent with earlier reports on pH1N1 influenza showing that-in contrast to findings in seasonal influenza-younger adults (,65 years old) may also be hospitalized for severe infections, and up to 40%-50% of them are previously healthy persons [1, 4, 10-14, 17, 21, 22, 30-32] . Diagnosis is difficult without PCR, because sensitivities of commonly used antigen assays are low [1, 9-11, 13, 28, 33] . We also found that though both pH1N1 and seasonal influenza caused significant complications, hospitalized patients with pH1N1 influenza had a greater risk of developing critical and fatal illnesses, especially in the absence of timely antiviral treatment [9, 10, 30, 34] . The ability to bind to both a2,6-and a2,3-linked cellular receptors and to replicate efficiently in lung tissues, lack of preexisting immunity, and impaired viral clearance may explain the higher propensity of the virus to cause severe pneumonitis and respiratory failure in susceptible individuals [1, 7, 12-14, 23, 28, 35, 36] . Extrapulmonary complications (eg, renal failure, severe diarrhea, encephalopathy, myocarditis) [11-15, 23, 37] , acute respiratory distress syndrome, multiorgan failure, and hemophagocytosis may also occur in such cases as a result of high-level viral replication and NOTE. Only patients who had not received antiviral treatment within 96 h after onset were included in this analysis (pandemic H1N1, n 5 89; seasonal influenza, n 5 371). Sex, onset-to-presentation interval, chronic lung disease, bacterial superinfection, complications, and hospital site were adjusted for in this final model. CI, confidence interval; OR, odds ratio.
cytokine dysregulation [1, 12-14, 17, 23, 34-37] . Our findings are supported by a large, population-based study on PCRconfirmed influenza, which showed that pH1N1 infection was associated with higher relative risk (4.2-5.1) of ICU admission than seasonal influenza [38] . Hospitalized patients with pH1N1 infections should be carefully monitored for disease progression, and in times of major outbreak, surge capacity (eg, ICU beds, ventilators) is likely important to handle critically ill patients with influenza [13] [14] [15] .
In addition, our results indicated that antiviral treatment may improve outcomes in adult patients hospitalized for pH1N1 infection [1, 10-13, 16, 17, 34, 39] and that treatment initiated within 96 h of onset may still confer benefit [12, 16, 17] . In fact, with timely treatment, mortality rates among hospitalized patients with pH1N1 influenza appeared no higher than those observed for seasonal influenza. Previous studies of patients hospitalized for seasonal influenza have shown that though the best clinical outcomes are seen with NAI treatment within 48 h, later treatment (%96 h) is also beneficial, albeit to a lesser extent [19, 20, 26, 40, 41] . A recent study on pH1N1-infected pregnant women also showed that although antiviral use within 2 days was associated with the lowest rates of ICU admission and death, a smaller benefit was evident with treatment given within 3-4 days [16] . Such finding is supported by virologic data from this cohort and others demonstrating high viral load and active viral replication in patients with pH1N1 pneumonia despite late presentation at 3-4 days after onset; in some cases, it was even more sustained (Supplementary Material 4) [23, 28, 37, 42, 43] . Any benefit associated with treatment started after 96 h cannot be excluded, but our analysis indicated that the extent of benefit will diminish as time elapses. Controlled studies are urgently required to determine the relative efficacy of late treatment and when antiviral will stop providing benefit [1, 19, 20, 26, 28] ; our data strongly support the recommendation to consider antivirals in all patients hospitalized for pH1N1 influenza if there is evidence of active viral replication, including in patients who present after .48 h, because of potential devastating outcomes [1, 2, 26] . Because the greatest benefit occurs with early treatment, the importance of early diagnosis and therapeutic intervention must be emphasized [1, 9, 10, 19, 20, 26, 28, 44] .
Furthermore, we found that bacterial superinfection occurred in at least 11%-15% of patients hospitalized for pH1N1 infection and was independently associated with adverse outcomes [11-13, 15, 17, 30, 38] . Influenza virus and bacteria act synergistically, and their combined role in causing fatal illness is increasingly recognized [15, 17, 27, 45] . In addition to antivirals, prompt detection and treatment of bacterial superinfection are advisable, both at presentation and during the hospital course [45, 46] . Interestingly, we found no excess bacterial superinfections between patients with pH1N1 and those with seasonal influenza (mainly H3N2), findings that agree with results from experimental or animal models [47] .
The strengths of our study included the comparison of 2 large cohorts of patients with laboratory-confirmed influenza diagnosed and managed at the same hospitals; detailed clinical data were collected with identical tools. Antiviral treatment, age, comorbid conditions, and other confounders were controlled for when outcomes between cohorts were compared [10, 16, 21, 22] . Our study is limited by its observational nature and use of historical controls; however, treatment bias is unlikely, because antivirals were offered to all patients with pH1N1 influenza after diagnosis, regardless of perceived severity, and there was major change in admission or management procedures during the study periods. Because RT-PCR is more sensitive than culture, it is possible that less severe infections with lower viral loads were included in the pandemic influenza cohort, leading to the apparently lower complication rate [1, 7, 21, 28] . Although increased numbers of severe infections and hospitalizations seen during the 2009 H1N1 pandemic might be related in part to a high disease burden in the population [7, 22] , this is unlikely to explain the higher rates of critical illness associated with pH1N1 influenza among patients hospitalized with complications. In fact, when younger, healthier adults were hospitalized during a more widespread ''seasonal'' epidemic, the overall proportion of ICU admission was lower, because critical illnesses seldom occur among younger patients with seasonal influenza [48] .
In conclusion, adults hospitalized for pH1N1 influenza had significant complications and mortality despite their younger age. Antiviral treatment given within 96 h after the onset of illness may improve clinical outcomes. Antiviral therapy should be considered in all patients hospitalized for severe influenza.
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